News
Rare disease and gene therapy stocks, battered in recent months by clinical and commercial setbacks, will likely benefit from the sudden departure this past week of Vinayak (Vinay) Prasad, MD, as ...
Vinay Prasad is my former student and friend. His departure from FDA is a loss for American medicine
It is hard to imagine someone more equipped and more dedicated to vetting treatments than Vinay Prasad,” writes his former ...
After turning down several new drugs and restricting use of another, Dr. Vinay Prasad drew the ire of the right-wing ...
But this time, the unknown is hitting the industry in a different way from when Prasad was tapped to lead CBER less than ...
Vinay Prasad was supposed to be the guy who kept Big Pharma in check. Now he’s gone.
Sources also say that the administration plans to split CBER in two, with one of the section focused entirely on vaccines.
Prasad came to the Food & Drug Administration in May, hoping to set high, evidence-based standards for new medicines. He didn't even last three months. The industry's power has never been clearer.
Alnylam Pharma raised its revenue outlook as its heart drug sees quick uptake. Biogen, Argenx, Sanofi, and Bristol Myers ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results